Arrowgrass Capital Partners Llp adds PharMerica Corporation (PMC) to its portfolio

PharMerica Corporation (PMC) : Arrowgrass Capital Partners Llp added new position in PharMerica Corporation during the most recent quarter end. The investment management firm now holds 212,481 shares of PharMerica Corporation which is valued at $4,702,205 , the company said in a statement filed on Aug 15, 2016 with the SEC.PharMerica Corporation makes up approximately 1.64% of Arrowgrass Capital Partners Llp’s portfolio.

Other Hedge Funds, Including , Invictus Rg Pte. Ltd. added PMC to its portfolio by purchasing 14,222 company shares during the most recent quarter which is valued at $314,733. PharMerica Corporation makes up approx 0.27% of Invictus Rg Pte. Ltd.’s portfolio.Credit Suisse Ag boosted its stake in PMC in the latest quarter, The investment management firm added 27,301 additional shares and now holds a total of 57,219 shares of PharMerica Corporation which is valued at $1,266,256.Blackrock Investment Management boosted its stake in PMC in the latest quarter, The investment management firm added 7,197 additional shares and now holds a total of 141,192 shares of PharMerica Corporation which is valued at $3,124,579.Boston Advisors boosted its stake in PMC in the latest quarter, The investment management firm added 105 additional shares and now holds a total of 19,985 shares of PharMerica Corporation which is valued at $531,001. PharMerica Corporation makes up approx 0.01% of Boston Advisors’s portfolio.

PharMerica Corporation opened for trading at $26.55 and hit $26.87 on the upside on Wednesday, eventually ending the session at $26.76, with a gain of 0.56% or 0.15 points. The heightened volatility saw the trading volume jump to 271,571 shares. Company has a market cap of $823 M.

On the company’s financial health, PharMerica Corporation reported $0.47 EPS for the quarter, based on the information available during the earnings call on Aug 9, 2016. Analyst had a consensus estimate of $0.47. The company had revenue of $519.60 million for the quarter, compared to analysts expectations of $508.31 million. The company’s revenue was up 4.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.48 EPS.

Many Wall Street Analysts have commented on PharMerica Corporation. PharMerica Corporation was Resumed by BofA/Merrill to “Buy” on Jun 7, 2016.

PharMerica Corporation is an institutional pharmacy services company. The Company has three operating segments: institutional pharmacy specialty infusion services and specialty oncology pharmacy. The Company’s core business institutional pharmacy segment provides pharmacy products and services to residents and patients in skilled nursing facilities nursing centers assisted living facilities hospitals and other long-term alternative care settings. The Company’s specialty infusion services segment provides specialty infusion services focused on providing pharmaceutical products and clinical services to patients in client facilities hospice and outside of hospital or nursing home settings. The Company’s specialty oncology pharmacy segment provides dispensing of oncology drugs care management and other related services to patients oncology practices and hospitals.

Leave a Reply

PharMerica Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on PharMerica Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.